See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

Experimental women's cancer drug boosts survival rates in notable study

Summary by Fox News
Researchers discuss encouraging findings on a new drug tested in a phase 3 trial, which showed significant improvement in patients with treatment-resistant ovarian cancer.

8 Articles

All
Left
Center
Right
1
Fox NewsFox News
Right

Experimental women's cancer drug boosts survival rates in notable study

Researchers discuss encouraging findings on a new drug tested in a phase 3 trial, which showed significant improvement in patients with treatment-resistant ovarian cancer.

·New York, United States
Read Full Article
BIOENGINEER.ORGBIOENGINEER.ORG

TRIM4 Influences hnRNPDL Degradation via Ubiquitin Pathway, Impacting

Ovarian cancer remains one of the most challenging gynecological malignancies, notorious for its late-stage diagnosis and poor survival rates. Despite ongoing advancements in oncological therapies, the urgent pursuit for innovative treatment strategies continues. Recent studies have shed light on the role of biomarkers in not just diagnosing, but also predicting, treatment responses in ovarian cancer patients. A prominent focus of this search ha…

Read Full Article
pharmafile.compharmafile.com

Corcept's relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint - Pharmafile

Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival in ROSELLA, the company’s phase 3 trial of the therapy. The ROSELLA trial enrolled 381 patients with platinum-resistant ovarian cancer across sites internationally. Patients were randomised 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. ROSELLA has dual primary […] The post Corcept’s…

Read Full Article
Clinical Trials ArenaClinical Trials Arena

Corcept's Phase III trial of ovarian cancer therapy shows PFS improvement

Corcept's Phase III trial of relacorilant with nab-paclitaxel has met its primary endpoint, demonstrating an improvement in PFS.The post Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement appeared first on Clinical Trials Arena.

Read Full Article
Mugglehead MagazineMugglehead Magazine

Corcept Therapeutics shares double on solid Phase 3 results for ovarian cancer treatment

Corcept Therapeutics shares double on solid Phase 3 results for ovarian cancer treatment, going well over 100% of its former price.

Read Full Article
oncnursingnews.comoncnursingnews.com

Relacorilant/Nab-Paclitaxel May Increase PFS, OS in Ovarian Cancer

Relacorilant in combination with nab-paclitaxel yielded higher PFS and OS in patients with platinum-resistant ovarian cancer vs nab-paclitaxel alone.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

onclive.com broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal